modakafusp alfa,bortezomib
takeda
['modakafusp']
modakfusp innate immunity enhancer in relapsed refractory mm patients shows preliminary efficacy at 1.5 mg iv q4 weeks even in patients refractory to anti-cd38 antibody and prior exposure to an anti-bcma therapy. phase 1/2 data presented by dr. vogl. #ash22 
Multiple Myeloma Oncologist